Ascendis Pharma A/S (NASDAQ:ASND) Price Target Raised to $352.00

Ascendis Pharma A/S (NASDAQ:ASND) had its target price increased by equities research analysts at TD Cowen from $341.00 to $352.00 in a report released on Friday, Benzinga reports. The brokerage presently has a “buy” rating on the biotechnology company’s stock. TD Cowen‘s price target would suggest a potential upside of 31.23% from the stock’s previous close.

ASND has been the subject of a number of other research reports. HC Wainwright reduced their price objective on Ascendis Pharma A/S from $344.00 to $335.00 and set a “buy” rating for the company in a research report on Friday. Bank of America dropped their target price on Ascendis Pharma A/S from $306.00 to $304.00 and set a “buy” rating on the stock in a research report on Monday, August 31st. Canaccord Genuity Group raised their price target on Ascendis Pharma A/S from $268.00 to $274.00 and gave the stock a “hold” rating in a research note on Friday. Cantor Fitzgerald raised their price target on Ascendis Pharma A/S from $300.00 to $315.00 and gave the stock an “overweight” rating in a research note on Friday. Finally, Royal Bank Of Canada lifted their price target on Ascendis Pharma A/S from $280.00 to $290.00 and gave the company an “outperform” rating in a report on Friday, August 14th. Nineteen investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $307.10.

Ascendis Pharma A/S Trading Up 3.5%

Shares of NASDAQ:ASND opened at $268.24 on Friday. The firm has a fifty day moving average of $242.58 and a two-hundred day moving average of $239.65. The company has a quick ratio of 2.32, a current ratio of 2.99 and a debt-to-equity ratio of 0.27. Ascendis Pharma A/S has a 12-month low of $188.07 and a 12-month high of $282.15. The firm has a market capitalization of $16.73 billion, a P/E ratio of 20.73 and a beta of 0.40.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings results on Friday, August 14th. The biotechnology company reported $1.03 earnings per share for the quarter, missing analysts’ consensus estimates of $1.71 by ($0.68). Ascendis Pharma A/S had a return on equity of 32.54% and a net margin of 70.99%. The company had revenue of $387.22 million during the quarter, compared to analyst estimates of $376.75 million. On average, equities analysts expect that Ascendis Pharma A/S will post 3.43 EPS for the current fiscal year.

Insider Buying and Selling at Ascendis Pharma A/S

In related news, SVP Mads Bodenhoff sold 3,000 shares of Ascendis Pharma A/S stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $270.19, for a total value of $810,570.00. Following the completion of the sale, the senior vice president owned 3,000 shares of the company’s stock, valued at approximately $810,570. The trade was a 50.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 40.00% of the company’s stock.

Hedge Funds Weigh In On Ascendis Pharma A/S

Several institutional investors have recently bought and sold shares of the stock. Allworth Financial LP boosted its stake in shares of Ascendis Pharma A/S by 103.4% during the 2nd quarter. Allworth Financial LP now owns 240 shares of the biotechnology company’s stock worth $64,000 after acquiring an additional 122 shares in the last quarter. EverSource Wealth Advisors LLC raised its stake in shares of Ascendis Pharma A/S by 34.0% in the 1st quarter. EverSource Wealth Advisors LLC now owns 272 shares of the biotechnology company’s stock valued at $62,000 after acquiring an additional 69 shares in the last quarter. Fifth Third Bancorp raised its stake in shares of Ascendis Pharma A/S by 48.4% in the 3rd quarter. Fifth Third Bancorp now owns 279 shares of the biotechnology company’s stock valued at $64,000 after acquiring an additional 91 shares in the last quarter. Parallel Advisors LLC raised its stake in shares of Ascendis Pharma A/S by 94.9% in the 1st quarter. Parallel Advisors LLC now owns 304 shares of the biotechnology company’s stock valued at $70,000 after acquiring an additional 148 shares in the last quarter. Finally, IFP Advisors Inc lifted its holdings in Ascendis Pharma A/S by 3,491.7% in the 2nd quarter. IFP Advisors Inc now owns 431 shares of the biotechnology company’s stock worth $115,000 after purchasing an additional 419 shares during the last quarter.

Top Ascendis Pharma A/S Stories

These are some of the ASND stories that stood out recently:

• Positive Sentiment: Ascendis reported Q3 product revenue of €366 million, up 89% year over year, led by YORVIPATH at €291 million. The company also reported better-than-expected earnings and revenue, and said it expects at least €600 million in operating cash flow for the full year. Ascendis Pharma Reports Third Quarter 2026 Financial Results
• Neutral Sentiment: HC Wainwright lowered its price target from $344 to $335 but kept a Buy rating, indicating continued optimism while trimming its valuation view. HC Wainwright recommendations
• Neutral Sentiment: The company granted 28,030 employee warrants, which may have a modest dilutive effect. Ascendis Pharma Grants 28,030 Employee Warrants

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a biopharmaceutical company headquartered in Denmark that develops medicines for rare diseases, with a focus on endocrinology. Founded in 2006, the company uses its TransCon technology platform to design therapies intended to provide sustained delivery of medicines. Its commercial products include SKYTROFA (lonapegsomatropin), a once-weekly growth hormone treatment for children with growth hormone deficiency, and YORVIPATH (palopegteriparatide), a treatment for adults with hypoparathyroidism.